- This topic has 0 replies, 1 voice, and was last updated 3 years, 6 months ago by
.
Viewing 0 reply threads
-
Posts
-
-
The webinar will review edaravone evidence, talk about the use of biomarkers to understand the effect of medical therapies, present the design of the REFINE-ALS study, and discuss how people can get involved in the study.
REFINE-ALS: A Much-Needed Biomarker Study of Edaravone (Radicava) in ALS
James D. Berry, MD, MPH, Massachusetts General Hospital
Thursday, November 14, 2019
4:00 – 5:00 PM EST
Note: if you miss the webinar, we will post a link to the replay once it is available.
-
Viewing 0 reply threads
- You must be logged in to reply to this topic.
